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Abstract  
Background: Most data on the clinical epidemiology of atrial fibrillation (AF) comes from 
Western populations, and data for Asians are limited. We investigated the lifetime risk and 
projected number of AF among Asians. The annual risks of adverse events amongst AF 
patients, time trends and the risks compared to non-AF patients were analyzed.     
Methods: From year 2000 to 2011, 289,559 patients aged ≥ 20 years experienced new-onset 
AF in Taiwan. The incidence, prevalence and lifetime risk of AF were calculated. The risk of 
adverse events amongst AF patients were analyzed and compared to that of age- and gender-
matched patients without AF.  
Results: The incidence of AF in year 2011 was 1.51 per 1000 person-years, with a lifetime 
risk of AF being appropriately 1 in 7 for subjects aged >20 years. The prevalence of AF is 
estimated to be 4.01% in 2050.  
Compared to patients without AF, AF was associated with an increased risk of mortality 
(adjusted hazard ratio 2.61), heart failure (3.31), ischemic stroke (3.34), dementia (1.56), 
sudden cardiac death (1.83), and myocardial infarction (1.62); all p value <0.01. The risks of 
ischemic stroke, heart failure and mortality were especially higher compared to non-AF 
patients within the initial period (approx. 6 months) after AF was first diagnosed.  
Conclusions: The burden of AF amongst Asian patients is increasing, with a lifetime risk of 
AF being appropriately 1 in 7. Optimized management of any associated comorbidities 
should be part of the holistic management approach for AF. 
Key words: atrial fibrillation, incidence, prevalence, lifetime risk, adverse events 
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Introduction 
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, and its 
prevalence is projected to rise continuously over the next few decades due to an ageing 
population.1 The lifetime risks for development of AF have been quoted as 1 in 4 for men and 
women 40 years of age and older based on the data of Framingham Heart Study.2 In the 
Rotterdam study, the lifetime risk of developing AF at the age of 55 years was 23.8% in men 
and 22.2% in women.3 In contrast to such extensive data in the white population,4 time trends 
in the incidence, prevalence and lifetime risks of AF amongst Asians are limited.  
AF has large impact on a person’s health. Historical studies have shown that AF is 
associated with an increased risk of ischemic stroke, mortality and heart failure.5-7 More 
recently, AF has been reported to be an important risk factor for dementia, myocardial 
infarction and sudden cardiac death.8-11 Again, most of the clinical epidemiology of AF has 
been based on studies that mainly enrolled Caucasian population in America and Europe, and 
the risk of adverse events of Asian AF patients has not been well studied. 
We investigated the incidence, prevalence, lifetime risk and projected number of AF 
among Asians. Second, we investigated the annual risks of adverse events amongst AF 
patients, time trends and the risks compared to non-AF patients.   
  .
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Methods 
Database 
This study used the “National Health Insurance Research Database (NHIRD)” released 
by the Taiwan National Health Research Institutes (NHRI). The National Health Insurance 
(NHI) system is a mandatory universal health insurance program which has been launched on 
March 1, 1995 that offers comprehensive medical care coverage to all Taiwanese residents. 
NHIRD consists of detailed health care data from >23 million enrollees, representing >99% 
of Taiwan’s population from January 1, 1996 to December 31, 2011. In this cohort dataset, 
the patients’ original identification numbers have been encrypted to protect their privacy, but 
the encrypting procedure was consistent, so that a linkage of the claims belonging to the same 
patient was feasible within the NHI database and can be followed continuously. The details 
about the Taiwan NHIRD could be found at the website of Taiwan NHRI 
(http://nhird.nhri.org.tw/en/Data_Files.html). 
Study population 
From January 1, 2000 to December 31, 2011, a total of 289,559 patients aged ≥ 20 years 
have experienced new-onset AF. The AF was assumed to be new-onset if no diagnosis of AF 
could be traced within the NHIRD from January 1, 1996 to the index date. The detailed 
health care data of each AF patients were available to December 31, 2011 unless mortality 
occurred earlier. AF was diagnosed using the International Classification of Diseases (ICD), 
Ninth Revision, Clinical Modification (ICD-9-CM) codes (427.31) registered by the 
physicians responsible for the treatments of patients. To ensure the accuracy of diagnosis, we 
defined patients with AF only when it was a discharge diagnosis or confirmed for at least 2 
times in the outpatient department. We defined the date of discharge or the date of the second 
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documented AF in the outpatient department as the index date. The diagnostic accuracy of 
AF using this definition in NHIRD has been validated previously.12,13 Among the AF cohort, 
158,283 patients (54.7%) were diagnosed using the discharge diagnosis. For patients who 
were diagnosed in the outpatient department (n = 131,276), the median durations between 
these 2 outpatient visits were 16 days (interquartile range = 7-56 days). For each AF patients, 
an age (same age in years)- and gender-matched subject without AF were identified from the 
NHIRD at the same index date, and the risk of adverse events were compared between AF 
and non-AF subjects. Patients were defined as non-AF patients if no any diagnosis of AF 
could be traced within the NHIRD.  
Incidence, prevalence and projected number of AF 
Crude incidence rates for AF of each year were calculated by dividing the number of 
incident cases of AF by the number of person-years accumulated by whole Taiwanese 
residents within 1 year. The person-years of follow up of each year are shown in 
Supplemental Table 1. The prevalence of AF was calculated by dividing the number of AF 
patients alive at the end of each year by the number of Taiwanese residents alive at the end of 
each year. The incidence and prevalence rates of AF for males and females for 10-year age 
strata were analyzed based on the incidence and prevalence rates in year 2011. For the 
calculation of lifetime risk, the method proposed by Sasieni et al. was used.14 The incidence 
of AF among patients with death free for each age attained during the 12-year period was 
calculated. Lifetime risk estimates reflect the sum of age-specific incidences from study entry 
to age at last observation.  
The formula used to calculate the projected prevalence of AF and its detailed 
descriptions are similar to the study by Lane et al.15 The projection of the prevalence of 
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AF,  , at age level i in year j was calculated iteratively based on age level incidence ri and 
mortality Mi as 
 
with the overall relative mortality of AF patients, RRAF, assumed to be constant across all 
ages. An annual constant increase in incidence may be given by q>0, also implying equal 
relative increase across age groups. Incidence of AF was based on the incidence rate of AF in 
Taiwan in year 2011 stratified for 5 age groups (20-29, 30-39, 40-49, 50-59, 60-69, 70-79 
and ≥80 years), whereas mortality rates were extracted from the Taiwan population statistics 
provided by the Department of Statistics, Taiwan Ministry of the Interior (TMI) in 2011. An 
excess mortality for AF compared to non-AF patients of HR = 2.61, that is, RRAF=2.61 
according to the results of the present study. Prevalence in 2011 was estimated directly from 
the AF cohort and used as a basis for the projection of prevalence from 2012 to 2050 on the 
assumption of a constant incidence (q=0). Using TMI projections of the Taiwan population 
size,  at age group i in year j, the expected number of AF patients at year j was 
obtained as   and the overall prevalence  . 
Definitions and risks of adverse events  
In the present study, we investigated six kinds of adverse events, including mortality, 
ischemic stroke (433.x, 434.x, 436), heart failure (402.01, 402.11, 402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 404.93, 428.x), dementia (290.0-290.4, 331.0), sudden cardiac death 
(427.5, 798.1, 798.2) and myocardial infarction (410.xx). The diagnostic accuracies of heart 
failure, myocardial infarction and ischemic stroke in Taiwan NHIRD have been validated 
before.16-18 We investigated the risk of first-time rather than recurrent events after incident 
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AF and aimed to provide a picture about the disease course, namely the subsequent risks of 
important adverse events after new-onset AF. Since the risks of ischemic stroke and 
myocardial infarction could be significantly reduced with the use of antithrombotic therapies, 
we analyzed these risks among patients who did not receive antithrombotic therapies within 
90 days after the index date. Incidence rate (per 100 person-years) of adverse events was 
calculated from dividing the number of event by person-time at risk, and the data were 
presented as the annual risk (%/year). 
The risk of ischemic stroke was analyzed among AF and compared to that of non-AF 
patients without history of ischemic stroke who did not receive antithrombotic therapies (n = 
143,684 in each groups). The risk of myocardial infarction was analyzed among AF and 
compared to that of non-AF patients without history of myocardial infarction who did not 
receive antithrombotic therapies (n = 135,065 in each groups). The risk of heart failure, 
dementia and sudden cardiac death were analyzed among AF and compared to that of non-
AF patients without history of these events, with a patient number of 166,740, 268,679 and 
288,180, respectively in each groups.  
Statistical analysis 
Data are presented as the mean value and standard deviation for continuous variables 
and proportions for categorical variables. The differences between normally distributed 
continuous values were assessed using an unpaired 2-tailed t test or one-way analysis of 
variance (ANOVA) for the comparisons of 3 groups. The differences between nominal 
variables were compared by Chi-square test. The cumulative incidence curves of adverse 
events were plotted using the Aalen–Johansen estimator with mortality being as the 
competing risk. The risk of adverse events for AF and non-AF patients were compared using 
Cox regression analyses which adjusted for age, gender and comorbidities, including 
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hypertension, diabetes mellitus, heart failure, vascular diseases, and previous history 
ischemic stroke/transient ischemic attack. We also investigated the hazard ratios (HRs) of 
mortality, heart failure and ischemic stroke of AF compared to non-AF patients in different 
timing periods (“one-month interval within 2 years” and “more than 2 years”) after the index 
date. Data were analyzed using the SPSS PASW statistical software (IBM corporation, 
Armonk, NY, USA), and all statistical significances were set at a p < 0.05. 
The present study was approved by the Institutional Review Board (IRB) at Taipei 
Veterans General Hospital (2016-03-002AC and 2017-07-003BC), Taipei, Taiwan and the 
informed consent of study subject was waived. 
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Results 
The mean age of the 289,559 AF patients was 71.5 ± 13.3 years, and 55.3% were men. 
Mean CHADS2 and CHA2DS2-VASc scores of overall AF cohort were 2.69 and 4.14, 
respectively; and hypertension was the most prevalent comorbidity, noted in 74.1% of 
patients. Table 1 presents the baseline characteristics of the AF cohort overall and by time 
period (200–2003, 2004–2007, and 2008–2011). There was clear evidence of an aging AF 
population, with the proportion of over 80-year-olds increasing from 25.7% in 2000–2003 to 
33.5% in 2008–2011. Also, the prevalences of important comorbidities at the time of AF 
diagnosis increased. Owing to the increase in age and comorbidities, the CHADS2 and 
CHA2DS2-VASc scores of incident AF patients diagnosed in each year showed a trend to 
become higher with successive year (Figure 1).  
Incidence, prevalence, lifetime risk and projected number of AF 
Figure 2A shows the incidence rate of AF from year 2000 to 2011. The incidence of AF 
in year 2011 was 1.51 per 1000 person-years (Figure 2A), with a stepwise increase with age 
(Figure 2B). The prevalence rate of AF increased from 0.46% to 1.07% over the 12 years, 
with a 2.33-fold increase (Figure 3A). Compared to subjects aged 50-59 years, subjects aged 
60-69 years had a 2.8-fold higher in AF (2.5% versus 0.9%), whereas subjected aged 70-79 
years had a nearly six-fold higher in AF (5.1% versus 0.9%) (Figure 3B). The projected 
prevalence rate was estimated to be 4.01% by the year 2050, and the projected number of AF 
patients was estimated to be 730,431 in Taiwan (Figure 4).  
The short-term, intermediate-term and lifetime risks of AF for subjects at different ages 
are shown in Table 1. For Chinese adults aged ≥20 years, the lifetime risk of AF was 
appropriately 1 in 7, being higher for males (1 in 6) compared to females (1 in 7) (Table 2). 
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Risk of adverse events among AF patients and the time trends 
Cumulative incidence curves of adverse events for AF patients are shown in Figure 5, 
while the annual risks of various adverse events after AF was diagnosed is shown in Figure 6.  
The annual risks were 9.17% for mortality, 8.53% for heart failure, 3.40% for ischemic stroke, 
2.22% for dementia, 1.05% for sudden cardiac death and 0.51% for myocardial infarction.  
The baseline characteristics of patients with or without AF are shown in Table 3. As 
expected, AF patients had more comorbidities than non-AF patients. Compared to patients 
without AF, AF was associated with an increased risk of mortality (adjusted hazard ratio 2.61, 
95%CI 2.58-2.64), heart failure (3.31, 3.26-3.36), ischaemic stroke (3.34, 3.26-3.42), 
dementia (1.56, 1.53-1.59), sudden cardiac death (1.83, 1.77-1.89), and myocardial infarction 
(1.62, 1.53-1.72); all p value <0.01 (Figure 6). The adjusted HRs of each events compared to 
patients without AF with mortality being the competing risk are also shown in Figure 6. 
Figure 7 shows the HRs of mortality, heart failure and ischemic stroke of AF patients 
compared to patients without AF for different time periods after AF was diagnosed. The risk 
of events of AF patients was especially higher than non-AF patients within the initial period 
(6 months) after AF was diagnosed (HR = 13.28, 95%CI 10.89-16.20 <within 6 months> 
versus 3.31, 95%CI 3.23-3.39 <after 6 months>, p value <0.001 for ischemic stroke; HR = 
5.86, 95%CI 5.25-6.55 <within 6 months> versus 3.05, 95%CI 3.00-3.09 <after 6 months>, p 
value <0.001 for heart failure). The one-year risk of adverse events after incident AF in each 
year remained broadly similar (Figure 8).   
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Discussion 
Our principal findings in this large nationwide cohort study of a Chinese population, are 
as follows: (i) The incidence of AF was 1.51 per 1000 person-years in year 2011, with a 
lifetime risk of AF being appropriately 1 in 6 for males and 1 in 7 for females aged >20 years; 
(ii) The prevalence of AF was 1.07% in 2011, and is estimated to be 4.01% in 2050; and (iii) 
Compared to patients without AF, AF was associated with an increased risk of mortality, 
heart failure, ischaemic stroke, dementia, sudden cardiac death, and myocardial infarction.    
Incidence, prevalence, lifetime risk of projection number of AF 
As far as we are aware, this is the largest and most comprehensive insight into the 
incidence, prevalence, lifetime risk and projected number of AF among Asians. In a recent 
review of the AF epidemiology in Asia, the incidence rate of AF was around 5.38 per 1000 
person-years based on the data of 10 studies which included 8,190 incident AF patients.19 
Most of the studies included in this systemic review enrolled specific populations, such as 
hyperuricemia, hyperlipidemia, osteoporosis, underweight, heavy alcohol consumption, and 
the elderly, and therefore, the incidence rate of AF may be overestimated and could not be 
generalized to general Asian population.  
Most prior data on AF incidence rates came from studies performed in Europe and 
North America. For example, the Rotterdam study enrolled subjects aged 55 years and above, 
where the AF incidence rate was around 9.9/1000 person-years.3 In a recent report from 
Netherlands studied subjects aged 28 to 75 years old, where the incidence rate of AF was 
3.3/1000 person-years.20 The reported incidence rate of AF ranged between 3.3 to 19.2 per 
1000 person-years among predominantly United States-based cohorot studies.3,21-24 In the 
present study, the AF incidence of Chinese population was around 1.51 per 1000 person-
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years, is lower compared to that of Caucasians. Also, the lifetime risk which was estimated 
based on the AF incidence rate for Chinese (1 in 6 for males and 1 in 7 for females) in the 
present study was lower than that reported from the Western countries (e.g. 1 in 4 in the 
Framingham Heart Study).2  
The prevalence rate of AF in our Chinese cohort was around 1.07% in year 2011, which 
substantially increased with age. Similar to the growing burden of AF all over the world,25 
the AF prevalence and the absolute number of AF patients will continuously increase in the 
coming decades in Taiwan based on the projected estimations. We have showed a clear trend 
demonstrating that incident AF patients were not only becoming older but having more 
comorbidities. It may suggest that although aging population and longer life expectancy are 
important reasons responsible for the increase in AF prevalence, the concurrent increase in 
hypertension, heart failure and other systemic diseases which are also more prevalent in the 
elderly may also contribute.    
In previous community studies, the AF prevalence rate ranged from 0.7% to 1.6% in 
Asia (0.7% in Korea,26 1.5% in Singapore,27 and 1.6% in Japan28). Similar to the incidence 
rate, the prevalence rate of AF in Asians was generally lower compared to the reported AF 
prevalence rates in Caucasians (e.g. 5.5% in Rotteram study).3,25 Although the precise 
mechanisms behind the differences of AF epidemiology between Asians and Caucasians 
remain unclear, part of the global variation may be attributable to a better surveillance in 
developed countries, and the prevalence of AF in some Asian countries is probably 
underestimated.25,29 Besides, the longer life expectancy and more prevalent cardiovascular 
risk factors and diseases, including smoking, obesity, hypertension, ischemic heart diseases 
and diabetes, in the developed western countries may also play important roles.29 
Furthermore, variants at several genetic loci are associated with the development of AF and 
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seem to differ in frequency between populations, and are likely to explain some of the ethnic 
variation observed in the prevalence of AF.29-31  
Risk of adverse events of Asian AF patients 
AF is associated with an increased risk of several adverse events other than ischemic 
stroke. In a recent meta-analyses which included 104 cohort studies involving 587,867 AF 
patients, AF was associated with an increased risk of all-cause mortality (relative risk [RR] 
1.46), ischemic stroke (RR 2.33), ischemic heart disease (RR 1.61), sudden cardiac death (RR 
1.88), heart failure (RR 4.99), chronic kidney disease (1.64), and peripheral arterial disease 
(1.31).32 Again, most of the studies included in this meta-analysis mainly enrolled Caucasians, 
and data about the risk of adverse events associated with AF in Asians are limited.  
Compared to the data mainly from non-Asians,32 the relative risks associated with AF in 
Asians were generally higher for ischemic stroke (3.34 versus 2.33), and mortality (2.61 
versus 1.46); lower for heart failure (3.31 versus 4.99); and similar for sudden cardiac death 
(1.83 versus 1.88) and myocardial infarction (1.62 versus 1.61). We demonstrated that the 
risks of ischemic stroke, heart failure and mortality were especially higher compared to non-
AF patients within the initial period (approx. 6 months) after AF was first diagnosed. During 
this vulnerable period, comprehensive evaluation and proactive management of associated 
comorbidities should be performed.  
Although the risk of ischemic stroke associated with AF compared to non-AF patients is 
higher than other events in our cohort with an adjusted HR of 3.34, the annual risks of 
mortality (9.17%/year) and heart failure (8.53/year) were higher than that of ischemic stroke 
(3.40%/year). In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) 
trial, the majority of deaths are not related to stroke among the anticoagulated AF 
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population.33 In a recent study from the Loire Valley AF project, cardiovascular deaths 
accounted for 54% and non-cardiovascular for 43% of deaths for AF patients.34 The three 
main causes of death were heart failure (29%), infection (18%), and cancer (12%), and only 
7% died from stroke. Thus, optimization of management of any underlying heart disease and 
associated comorbidities should be part of the holistic management approach to improve 
patient care in AF.  
Time trends of risk scores and risks of adverse events 
In the present study, we demonstrated that the risk of adverse events of AF patients 
remained similar and did not decrease over the study period despite improvements in our 
understanding and management of AF. Nonetheless, only around 15% of AF patients received 
appropriate treatments of stroke prevention according to the guideline recommendations in 
Taiwan.35  Also, more than 50% of AF patients did not receive rate control treatment which 
was associated with a lower risk of mortality.36  We also found that the baseline stroke scores 
of newly-diagnosed AF patients were increasingly higher with each subsequent year, which 
may reflect greater longevity and improved detection of risk factors.  
Study limitations 
There are several limitations in the present study, given the natures of the nationwide 
registry dataset we used. First, the subtypes of AF (paroxysmal or non-paroxysmal) were not 
available. Second, the diagnoses of AF and adverse events were based on the ICD-9-CM 
codes registered by physicians responsible for the care of the patients, and no direct 
evaluations for events were performed. Although the diagnostic accuracies of AF, heart 
failure, myocardial infarction and ischemic stroke in Taiwan NHIRD have been 
validated,12,13,16-18 the diagnostic accuracies of these diseases in an insurance database may 
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not be as accurate as that of electronic medical records. Third, we investigated the risk of 
ischemic stroke and myocardial infarction among patients who did not receive antithrombotic 
therapies within 90 days after incident AF. Since patients may receive antithrombotic 
therapies during the follow up, the true risk of ischemic stroke and myocardial infarction 
without treatment of AF patients may be higher than we reported here. Fourth, the lifetime 
risk and prevalence projection of AF were estimated using the data collected from year 2000 
to 2011 without considering effects of birth-cohort and changes in population demographics 
and other comorbidities associated with the occurrence of AF. Also, the projected prevalence 
rate and patient number of AF were estimated based on and sensitive to several assumptions 
of the model, such as RRAF = 2.61, q = 0, etc. Fifth, although we have shown a higher AF 
prevalence rate among older patients, we were not able to clearly analyze how much of this 
increase is due to concurrent increases in hypertension, heart failure or other comorbidities in 
the elderly. Last, the present study only enrolled Chinese patients, whether the results can be 
extrapolated to other populations remains uncertain.    
 
Conclusion  
The burden of AF amongst Asian patients is increasing, with a lifetime risk of AF being 
appropriately 1 in 7. This results in a significant mortality, heart failure, ischaemic stroke, 
dementia, sudden cardiac death and myocardial infarction. Optimized management of any 
associated comorbidities should be part of the holistic management approach for AF. 
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Table 1. Baseline demographic and clinical characteristics of incident AF 
 
Variables 
Overall  
2000-2011 
(n = 289,559) 
2000 - 2003 
(n = 88,341) 
2004 - 2007 
 (n = 96,673) 
2008 - 2011 
 (n =104,545) P value 
Age (years), mean (SD) 71.5 (13.3) 70.9 (12.8) 71.5 (13.3) 71.9 (13.6) < 0.001 
Distribution of age, n (%)     < 0.001 
20–29 years old 1,804 (0.6) 553 (0.6) 629 (0.7) 622 (0.6)  
30–39 years old 4,615 (1.6) 1,493 (1.7) 1,491 (1.5) 1,631 (1.6)  
40–49 years old 13,970 (4.8) 4,375 (5.0) 4,796 (5.0) 4,799 (4.6)  
50–59 years old 31,909 (11.0) 8,656 (9.8) 10,765 (11.1) 12,488 (11.9)  
60–69 years old 55,545 (19.2) 18,275 (20.7) 18,133 (18.8) 19,137 (18.3)  
70–79 years old 95,191 (32.9) 32,267 (36.5) 32,091 (33.2) 30,833 (29.5)  
≥ 80 years old 86,525 (29.9) 22,722 (25.7) 28,768 (29.8) 35,035 (33.5)  
Gender (male), n (%) 160,185 (55.3) 49,249 (55.7) 53,207 (55.0) 57,729 (55.2) 0.006 
Comorbidities, n (%)      
Hypertension 214,448 (74.1) 59,363 (67.2) 72,896 (75.4) 82,189 (78.6) < 0.001 
Diabetes mellitus 89,440 (30.9) 21,641 (24.5) 30,280 (31.3) 37,519 (35.9) < 0.001 
Congestive heart failure 122,819 (42.4) 36,033 (40.8) 41,698 (43.1) 45,088 (43.1) < 0.001 
Previous stroke/transient ischemic attack 107,555 (37.1) 28,040 (31.7) 36,846 (38.1) 42,669 (40.8) < 0.001 
Previous vascular diseases  75,251 (26.0) 16,275 (18.4) 25,792 (26.7) 33,184 (31.7) < 0.001 
CHADS2 score, mean (SD) 2.69 (1.67) 2.40 (1.57) 2.74 (1.66) 2.89 (1.71) < 0.001 
CHA2DS2-VASc score, mean (SD) 4.14 (2.10) 3.77 (1.95) 4.20 (2.10) 4.39 (2.19) < 0.001 
Follow-up (years), mean (SD) 3.72 (3.24) 5.82 (4.02) 4.11 (2.44) 1.58 (1.17)  
 
SD = standard deviation 
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Table 2. Age-specific short- and intermediate-term and lifetime risk estimates for atrial fibrillation 
Index Age  
(Years) 
Short- and Intermediate-Term Risk of AF Lifetime Risk 10 years  20 years  30  years  40  years  50  years  60  years  70  years  
All                
20-29 0.05(0.04-0.06)  0.18(0.16-0.19)  0.53(0.50-0.55)  1.44(1.40-1.48)  2.90(2.84-2.96)  5.13(5.05-5.20)  7.33(7.24-7.42)  7.84(7.75-7.93)  1 to 13 
30-39 0.11(0.10-0.12)  0.42(0.40-0.44))  1.23(1.20-1.27)  2.52(2.47-2.57)  4.49(4.43-4.56)  6.44(6.36-6.52)    6.89(6.81-6.97)  1 to 15 
40-39 0.33(0.31-0.35)  1.19(1.16-1.23)  2.56(2.51-2.62)  4.66(4.59-4.73)  6.74(6.65-6.82)      7.21(7.13-7.30)  1 to 14 
50-59 0.96(0.93-0.99)  2.49(2.44-2.54)  4.83(4.76-4.90)  7.14(7.05-7.23)        7.67(7.58-7.77)  1 to 13 
60-69 2.74(2.67-2.82)  6.94(6.82-7.06)  11.08(10.93-11.23)          12.02(11.88-12.19)  1 to 8 
70-79 6.75(6.60-6.90)  13.42(13.21-13.66)            14.96(14.73-15.18)  1 to 7 
≥ 80 13.9(13.6-14.2)              21.67(20.35-22.99)  1 to 5 
Total               15.11(14.93-15.29)  1 to 7 
 
                 
Male                  
20-29 0.07(0.05-0.08)  0.24(0.22-0.26)  0.73(0.69-0.77)  1.93(1.87-2.00)  3.70(3.61-3.79)  5.97(5.85-6.08)  8.16(8.03-8.30)  8.58(8.45-8.72)  1 to 12 
30-39 0.16(0.14-0.18)  0.61(0.57-0.64)  1.70(1.65-1.76)  3.32(3.24-3.40)  5.39(5.28-5.49)  7.39(7.27-7.52)    7.78(7.65-7.90)  1 to 13 
40-39 0.47(0.44-0.50)  1.61(1.55-1.67)  3.30(3.22-3.38)  5.46(5.35-5.57)  7.56(7.43-7.68)      7.96(7.83-8.08)  1 to 13 
50-59 1.28(1.23-1.34)  3.17(3.08-3.25)  5.59(5.47-5.70)  7.94(7.80-8.07)        8.38(8.24-8.52)  1 to 12 
60-69 3.46(3.33-3.58)  7.89(7.70-8.07)  12.19(11.96-12.41)          13.00(12.77-13.24)  1 to 8 
70-79 7.49(7.26-7.72)  14.75(14.43-15.08)            16.13(15.80-16.47)  1 to 6 
≥ 80 13.9(13.4-14.3)              20.75(19.24-22.26)  1 to 5 
Total               16.92(16.66-14.20)  1 to 6 
                  
Female                  
20-29 0.03(0.02-0.04)  0.11(0.10-0.13)  0.32(0.29-0.34)  0.95(0.90-1.00)  2.10(2.03-2.16)  4.29(4.19-4.38)  6.49(6.37-6.61)  7.09(6.97-7.21)  1 to 14 
30-39 0.07(0.06-0.08)  0.25(0.22-0.27)  0.79(0.75-0.83)  1.77(1.71-1.83)  3.65(3.57-3.74)  5.54(5.44-5.65)    6.06(5.95-6.16)  1 to 17 
40-39 0.19(0.17-0.21)  0.78(0.74-0.82)  1.84(1.78-1.91)  3.88(3.79-3.97)  5.93(5.82-6.04)      6.49(6.37-6.60)  1 to 15 
50-59 0.65(0.61-0.69)  1.83(1.77-1.90)  4.09(4.00-4.19)  6.37(6.25-6.49)        6.89(6.86-7.11)  1 to 14 
60-69 2.08(1.99-2.17)  6.05(5.90-6.21)  10.05(9.86-10.25)          11.14(10.93-11.35)  1 to 9 
70-79 6.12(5.93-6.32)  12.29(12.01-12.56)            13.95(13.66-14.24)  1 to 7 
≥ 80 13.9(13.5-14.4)              21.86(20.03-23.69)  1 to 5 
Total               14.63(14.38-14.89)  1 to 7 
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Table 3. Baseline demographic and clinical characteristics of AF and non-AF 
populations 
 
Variables AF population (n = 289,559) 
Non-AF population 
(n = 289,559) P value 
Age (years), mean (SD) 71.5(13.3) 71.5(13.3) 0.995 
Distribution of age, n (%)   1.000 
20–29 years old 1,804 (0.6) 1,804 (0.6)  
30–39 years old 4,615 (1.6) 4,615 (1.6)  
40–49 years old 13,970 (4.8) 13,970 (4.8)  
50–59 years old 31,909 (11.0) 31,909 (11.0)  
60–69 years old 55,545 (19.2) 55,545 (19.2)  
70–79 years old 95,191 (32.9) 95,191 (32.9)  
≥ 80 years old 86,525 (29.9) 86,525 (29.9)  
Gender (male), n (%) 160,185 (55.3) 160,185 (55.3) 1.000 
Comorbidities, n (%)    
Hypertension 214,448 (74.1) 161,012 (55.6) < 0.001 
Diabetes mellitus 89,440 (30.9) 68,845 (23.8) < 0.001 
Congestive heart failure 122,819 (42.4) 34,180 (11.8) < 0.001 
Previous stroke/transient ischemic attack 107,555 (37.1) 47,552 (16.4) < 0.001 
Previous vascular diseases  75,251 (26.0) 14,286 (4.9) < 0.001 
CHADS2 score, mean (SD) 2.69 (1.67) 1.72 (1.25) < 0.001 
CHA2DS2-VASc score, mean (SD) 4.14 (2.10) 2.95 (1.92) < 0.001 
Follow-up (years), mean (SD) 3.72 (3.24) 4.73 (3.29) < 0.001 
 
SD = standard deviation 
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Figure Legends 
 
Figure 1. CHADS2 and CHA2DS2-VASc scores of incident AF patients in each year. The 
CHADS2 and CHA2DS2-VASc scores of incident AF patients diagnosed in each year showed 
a trend to became higher with successive year.  
 
Figure 2. Incidence rate of AF stratified by age and sex. The incidence rates of AF form 
year 2000 to 2011 are shown in Figure 2A. The incidence of AF in year 2011 was 1.51 per 
1000 person-years (Figure 2A), with a stepwise increase with age (Figure 2B). AF = atrial 
fibrillation. 
 
Figure 3. Prevalence rate of AF stratified by age and sex. The prevalence rate of AF 
continuously increased from 0.46% to 1.07% during the 12 years, with a 2.33-fold increase 
(Figure 3A).  The prevalence rate substantially increased for subjects aged above 60 years 
(Figure 3B). AF = atrial fibrillation. 
 
Figure 4. The projection number and prevalence rate of AF. The projected prevalence rate 
of AF continuously increases to 4.01% in year 2050, and there will be 730,431 AF patients in 
Taiwan.  AF = atrial fibrillation. 
 
Figure 5. Cumulative incidence curves of adverse events.  
*The risks of different adverse events were investigated among different subpopulations, as 
mentioned in the method section.  
 
Figure 6. The annual risks of adverse events of AF patients and the hazard ratios 
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compared to patients without AF. The annual risk of adverse events ranged from 0.51% for 
myocardial infarction to 9.17% for mortality. Compared to patients without AF, AF was 
associated with a 1.56- to 3.34-fold increase of various events after the adjustment for age, 
gender and comorbidities.  
*The risks of different adverse events were investigated among different subpopulations, as 
mentioned in the method section.  
 
Figure 7. Risk of mortality, heart failure and ischemic stroke of AF patients compared 
to non-AF patients in different time periods. The risk of events of AF patients was 
especially higher than non-AF patients within the initial period after AF was diagnosed.  
*The risks of different adverse events were investigated among different subpopulations, as 
mentioned in the method section. 
Figure 8. Trend of 1-year risk of adverse events after AF was diagnosed in each year. 
The one-year risk of adverse events after incident AF in each year remained broadly similar.   
*The risks of different adverse events were investigated among different subpopulations, as 
mentioned in the method section. 
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Supplemental Table 1. Number of new-onset AF and person-years of follow up in each year 
Year Number of New-onset AF Person-years 
2000 22,819 15,088,006 
2001 22,012 15,441,420 
2002 22,263 15,794,581 
2003 21,247 16,067,287 
2004 23,343 16,349,526 
2005 25,057 16,627,835 
2006 23,430 16,888,511 
2007 24,843 17,276,161 
2008 24,939 17,516,335 
2009 25,254 17,719,832 
2010 26,887 17,934,672 
2011 27,465 18,170,918 
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